|
China-DE-DE Azienda Directories
|
Azienda News:
- Considerations for the Use of Artificial Intelligence To Support . . .
Although you can comment on any guidance at any time (see 21 CFR 10 115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the
- FDA plans to release AI drug development guidance this year
The US Food and Drug Administration (FDA) plans to release a draft guidance this year on the use of artificial intelligence machine learning (AI ML) to support drug development The guidance will be informed by the agency@s experience in reviewing submissions containing AI ML elements, as well as feedback it received on two discussion papers on the topic released last year, said Tala Fakhouri
- FDA Releases Highly Anticipated Draft Guidance Documents on Artificial . . .
FDA has kicked off the new year by publishing two highly-anticipated draft guidance documents concerning artificial intelligence (AI): Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations (“Device AI Draft Guidance”); and Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug
- FDA’s views on AI are evolving - POLITICO
The paper received more than 800 comments from 65 organizations, said Tala Fakhouri, the FDA’s associate director for data science and AI policy Between 2016 and 2022, the agency reviewed more
- FDA Issues Comprehensive Draft Guidance for Developers of Artificial . . .
The FDA, an agency within the U S Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines
- FDA Proposes Framework to Advance Credibility of AI Models Used for . . .
“The FDA is committed to supporting innovative approaches for the development of medical products by providing an agile, risk-based framework that promotes innovation and ensures the agency’s
- FDA official sets out approach to AI in medical devices
The FDA has clarified its thinking through guidance documents and standards as it regulates a growing number of medical devices with an AI or machine learning component In 2021, the agency collaborated with Health Canada and the U K ’s Medicines and Healthcare products Regulatory Agency to set out guiding principles for good machine learning practice
|
|